PMH21 COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73942-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)73942-5/fulltext
Section Title :
Section Order :
424
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73942-5&doi=10.1016/S1098-3015(10)73942-5